NCT03604328View on ClinicalTrials.gov

Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions

Open-angle Glaucoma

Interventions

DRUG

PA5108

single ocular implant, administered on day 1

Trial Locations (2)

3000

Melbourne Eye Specialists, Melbourne

3002

Centre for Eye Research Australia, East Melbourne

Sponsors

Lead Sponsor

PolyActiva Pty Ltd

All Listed Sponsors

lead

PolyActiva Pty Ltd

INDUSTRY

NCT03604328 - Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma | Biotech Hunter | Biotech Hunter